First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis

First‐line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)‐negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS;

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of cancer 2023-02, Vol.152 (4), p.749-760
Hauptverfasser:	Liu, Tianshu, Bai, Yuxian, Lin, Xiaoyan, Li, Wei, Wang, Jufeng, Zhang, Xiaochun, Pan, Hongming, Bai, Chunmei, Bai, Li, Cheng, Ying, Zhang, Jingdong, Zhong, Haijun, Ba, Yi, Hu, Wenwei, Xu, Ruihua, Guo, Weijian, Qin, Shukui, Yang, Nong, Lu, Jianwei, Shitara, Kohei, Lei, Ming, Li, Mingshun, Bao, Nicole, Chen, Tian, Shen, Lin
Format:	Artikel
Sprache:	eng
Schlagworte:	5-Fluorouracil Adenocarcinoma Adenocarcinoma - pathology Antineoplastic Combined Chemotherapy Protocols Asian Continental Ancestry Group Cancer Cancer Therapy and Prevention Chemotherapy East Asian People Epidermal growth factor ErbB-2 protein Esophageal cancer Esophageal Neoplasms - pathology Esophagogastric Junction - pathology Esophagus Gastric cancer gastrointestinal neoplasms Humans Immunotherapy Ipilimumab - therapeutic use Medical research Metastases Metastasis Monoclonal antibodies nivolumab Nivolumab - therapeutic use Oxaliplatin Oxaliplatin - therapeutic use Response rates Safety stomach neoplasms Stomach Neoplasms - pathology Survival Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	First‐line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)‐negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS;
ISSN:	0020-7136 1097-0215
DOI:	10.1002/ijc.34296